Clinical trial
Study of Troxatyl™ Administered by Continuous Infusion to Subjects With…
NCT00104468 · SGX Pharmaceuticals, Inc., Industry · Terminated
Key facts
| NCT number | NCT00104468 |
|---|---|
| Title | Study of Troxatyl™ Administered by Continuous Infusion to Subjects With Refractory Acute Myelogenous Leukemia (AML) |
| Official title | An Open-Label, Single-Arm, Multi-Center, Phase I Study of Troxatyl™ (Troxacitabine) Administered by Continuous Infusion in Subjects With Refractory Acute Myelogenous Leukemia |
| Lead sponsor | SGX Pharmaceuticals, Inc., Industry |
| Status | Terminated |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Acute Myelogenous Leukemia |
| Intervention type | Drug |
| Interventions | Troxatyl™ (Cytotoxic Chemotherapeutic) |
| Enrollment | 50 |
| Start date | Apr 1, 2003 |
| Primary completion | Jun 1, 2007 |
| Completion | Jun 1, 2007 |
| First posted | Mar 1, 2005 |
| Last update posted | Jan 17, 2008 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: